Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL.
Ritchie CW, et al. Among authors: beyreuther k.
Arch Neurol. 2003 Dec;60(12):1685-91. doi: 10.1001/archneur.60.12.1685.
Arch Neurol. 2003.
PMID: 14676042
Clinical Trial.